FTC Approves Final Order Preserving Competition for Development and Marketing of Steroid Injectable Drug
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Hikma Pharmaceuticals plc’s $375 million acquisition of Custopharm, Inc. likely would...